Exenatide improves glucocorticoid-induced glucose intolerance in mice

Ruiying Zhao1,2*, Enrique Fuentes-Mattei1,2*, Guermarie Velazquez-Torres1,3, Chun-Hui Su1,2, Jian Chen1, Mong-Hong Lee1,2, Sai-Ching Jim Yeung4,51Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Program in Genes and Development, 3Progra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruiying Zhao, Enrique Fuentes-Mattei, Guermarie Velazquez-Torres, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/d1956e1105bc444082d4e5ddd2627293
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1956e1105bc444082d4e5ddd2627293
record_format	dspace
spelling	oai:doaj.org-article:d1956e1105bc444082d4e5ddd26272932021-12-02T07:11:41ZExenatide improves glucocorticoid-induced glucose intolerance in mice1178-7007https://doaj.org/article/d1956e1105bc444082d4e5ddd26272932011-01-01T00:00:00Zhttp://www.dovepress.com/exenatide-improves-glucocorticoid-induced-glucose-intolerance-in-mice-a6144https://doaj.org/toc/1178-7007Ruiying Zhao1,2, Enrique Fuentes-Mattei1,2, Guermarie Velazquez-Torres1,3, Chun-Hui Su1,2, Jian Chen1, Mong-Hong Lee1,2, Sai-Ching Jim Yeung4,51Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Program in Genes and Development, 3Program in Cancer Biology, Graduate School of Biomedical Sciences, University of Texas Health Science Center in Houston, Houston, TX, USA; 4Department of Endocrine Neoplasia and Hormonal Disorders, 5Department of Emergency Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA *Both authors contributed equally.Abstract: Exenatide is an incretin mimetic that is recently available in the US for the treatment of diabetes. There is a paucity of information on the effects of exenatide in glucocorticoid (GC)-induced diabetes. Although the effect of continuous intravenous infusion of exenatide on GC-induced glucose intolerance has been investigated before in healthy human males receiving oral prednisolone, we investigated the efficacy of a single subcutaneous dose of exenatide (3 &micro;g/kg) in lowering blood glucose in GC-induced glucose intolerance in C57BL/6 mice. In a longitudinal experiment, the area under the curve (AUC) of oral glucose tolerance tests (OGTT) significantly increased after dexamethasone (P = 0.004), which was subsequently decreased by exenatide (P &lt; 0.001). A cross-sectional experiment showed that exenatide improved glucose tolerance compared with placebo in a mouse model of dexamethasone-induced glucose intolerance. AUC of OGTT in the exenatide group were significantly (P &lt; 0.001) lower than in the placebo group. Insulin tolerance tests (ITT) demonstrated that exenatide decreased the ability of the mice to tolerate insulin compared with placebo. The AUC of ITT in the exenatide group were also significantly (P = 0.006) lower than in the placebo group. In conclusion, a single dose of exenatide was able to decrease glucose intolerance and insulin resistance in these placebo-controlled experiments. Future clinical trials are justified to investigate the role of exenatide in the treatment of GC-induced glucose intolerance/diabetes.Keywords: exenatide, dexamethasone, glucocorticoid, insulin resistance, mouse model Ruiying ZhaoEnrique Fuentes-MatteiGuermarie Velazquez-Torreset alDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2011, Iss default, Pp 61-65 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Ruiying Zhao Enrique Fuentes-Mattei Guermarie Velazquez-Torres et al Exenatide improves glucocorticoid-induced glucose intolerance in mice
description	Ruiying Zhao1,2, Enrique Fuentes-Mattei1,2, Guermarie Velazquez-Torres1,3, Chun-Hui Su1,2, Jian Chen1, Mong-Hong Lee1,2, Sai-Ching Jim Yeung4,51Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Program in Genes and Development, 3Program in Cancer Biology, Graduate School of Biomedical Sciences, University of Texas Health Science Center in Houston, Houston, TX, USA; 4Department of Endocrine Neoplasia and Hormonal Disorders, 5Department of Emergency Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA *Both authors contributed equally.Abstract: Exenatide is an incretin mimetic that is recently available in the US for the treatment of diabetes. There is a paucity of information on the effects of exenatide in glucocorticoid (GC)-induced diabetes. Although the effect of continuous intravenous infusion of exenatide on GC-induced glucose intolerance has been investigated before in healthy human males receiving oral prednisolone, we investigated the efficacy of a single subcutaneous dose of exenatide (3 &micro;g/kg) in lowering blood glucose in GC-induced glucose intolerance in C57BL/6 mice. In a longitudinal experiment, the area under the curve (AUC) of oral glucose tolerance tests (OGTT) significantly increased after dexamethasone (P = 0.004), which was subsequently decreased by exenatide (P &lt; 0.001). A cross-sectional experiment showed that exenatide improved glucose tolerance compared with placebo in a mouse model of dexamethasone-induced glucose intolerance. AUC of OGTT in the exenatide group were significantly (P &lt; 0.001) lower than in the placebo group. Insulin tolerance tests (ITT) demonstrated that exenatide decreased the ability of the mice to tolerate insulin compared with placebo. The AUC of ITT in the exenatide group were also significantly (P = 0.006) lower than in the placebo group. In conclusion, a single dose of exenatide was able to decrease glucose intolerance and insulin resistance in these placebo-controlled experiments. Future clinical trials are justified to investigate the role of exenatide in the treatment of GC-induced glucose intolerance/diabetes.Keywords: exenatide, dexamethasone, glucocorticoid, insulin resistance, mouse model
format	article
author	Ruiying Zhao Enrique Fuentes-Mattei Guermarie Velazquez-Torres et al
author_facet	Ruiying Zhao Enrique Fuentes-Mattei Guermarie Velazquez-Torres et al
author_sort	Ruiying Zhao
title	Exenatide improves glucocorticoid-induced glucose intolerance in mice
title_short	Exenatide improves glucocorticoid-induced glucose intolerance in mice
title_full	Exenatide improves glucocorticoid-induced glucose intolerance in mice
title_fullStr	Exenatide improves glucocorticoid-induced glucose intolerance in mice
title_full_unstemmed	Exenatide improves glucocorticoid-induced glucose intolerance in mice
title_sort	exenatide improves glucocorticoid-induced glucose intolerance in mice
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/d1956e1105bc444082d4e5ddd2627293
work_keys_str_mv	AT ruiyingzhao exenatideimprovesglucocorticoidinducedglucoseintoleranceinmice AT enriquefuentesmattei exenatideimprovesglucocorticoidinducedglucoseintoleranceinmice AT guermarievelazqueztorres exenatideimprovesglucocorticoidinducedglucoseintoleranceinmice AT etal exenatideimprovesglucocorticoidinducedglucoseintoleranceinmice
_version_	1718399603967000576

Exenatide improves glucocorticoid-induced glucose intolerance in mice

Ejemplares similares